Последние исследования

EudraCT Number: 2022-003865-39

Sponsor Protocol Number: WSG-AM12

Start Date: 2023-05-04

Sponsor Name: Westdeutsche Studiengruppe GmbH

Full Title: NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+pertuzumab in HER2+ early breast cancer

Medical condition: HER2+ early breast cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10006192	Breast cancer NOS	LLT
	23.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10065430	HER2 positive breast cancer	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-003951-41

Sponsor Protocol Number: BFS-AS-40184

Start Date: 2023-05-04

Sponsor Name: Teva Branded Pharmaceutical Products R&D, Inc.

Full Title: CONNected Electronic Inhalers Asthma Control Trial 3 (“CONNECT 3”), a 24-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison Study of Standard of Care Treatment Versus th...

Medical condition: Asthma

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2023-000033-33

Sponsor Protocol Number: 83631

Start Date: 2023-05-03

Sponsor Name: Maastricht University

Full Title: Short-term safety and efficacy of ketohexokinase inhibition in patients with hereditary fructose intolerance.

Medical condition: Hereditary fructose intolerance

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10010331 - Congenital, familial and genetic disorders	10019878	Hereditary fructose intolerance	PT
	20.1	10010331 - Congenital, familial and genetic disorders	10017397	Fructose intolerance hereditary	LLT
	21.0	10027433 - Metabolism and nutrition disorders	10072104	Fructose intolerance	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Completed)

Trial results: (No results available)

EudraCT Number: 2022-003056-14

Sponsor Protocol Number: VTX958-203

Start Date: 2023-05-03

Sponsor Name: Ventyx Biosciences, Inc

Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Patients with Active Psoriatic Arthritis

Medical condition: Active Psoriatic Arthritis

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	100000004859	10037160	Psoriatic arthritis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) BG (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-004411-11

Sponsor Protocol Number: NeoTreme

Start Date: 2023-05-03

Sponsor Name: University Hospital Schleswig-Holstein, Campus Lübeck

Full Title: Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (NeoTreme)

Medical condition: Intrahepatic cholangiocarcinoma

Disease:	Version	SOC Term	Classification Code	Term	Level
	27.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10073077	Intrahepatic cholangiocarcinoma	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003452-14

Sponsor Protocol Number: SBC007C401

Start Date: 2023-05-02

Sponsor Name: Berlin Cures GmbH

Full Title: A prospective, double-blind, randomised, parallel group, placebo controlled, multicentre, Phase II study to investigate the efficacy, GPCR autoantibody neutralising effect, safety, and tolerability...

Medical condition: long Covid

Disease:	Version	SOC Term	Classification Code	Term	Level
	25.1	10021881 - Infections and infestations	10087832	COVID-19 rebound	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing) ES (Ongoing) FI (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003532-73

Sponsor Protocol Number: ADVANCE-AD04-001

Start Date: 2023-05-02

Sponsor Name: ADvantage Therapeutics GmbH

Full Title: A Phase 2b, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients with Early Alzheimer’s Disease - ADVANCE

Medical condition: early Alzheimer’s disease

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029205 - Nervous system disorders	10001897	Alzheimer's disease (incl subtypes)	HLT
	20.0	10029205 - Nervous system disorders	10001896	Alzheimer's disease	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SK (Ongoing) BG (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-005551-36

Sponsor Protocol Number: NL79416.018.21

Start Date: 2023-05-01

Sponsor Name: Amsterdam University Medical Center, AMC

Full Title: Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients with Cardiogenic Shock from Acute Myocardial Infarction: A Multicenter Randomized...

Medical condition: Myocardial infarction related cardiogenic shock

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2022-003866-19

Sponsor Protocol Number: 83336

Start Date: 2023-05-01

Sponsor Name: Amsterdam UMC location AMC

Full Title: The effect of low-dose rhythmic 17-β-estradiol administration on bone turnover in postmenopausal women

Medical condition: Osteoporosis prevention

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults

Gender: Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003004-33

Sponsor Protocol Number: AR-DEX-22-01

Start Date: 2023-04-26

Sponsor Name: Areteia Therapeutics, Inc.

Full Title: A randomized, double-blind, placebo-controlled, parallel group study to assess the efficacy, safety, and tolerability of dexpramipexole administered orally for 52 weeks in participants with severe ...

Medical condition: Severe Eosinophilic Asthma

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10038738 - Respiratory, thoracic and mediastinal disorders	10068462	Eosinophilic asthma	LLT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: BG (Ongoing) PL (Ongoing)

Trial results: (No results available)

Последние исследования

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства